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1. Introduction
Despite the use of preventive measures, particularly 
hepatitis B virus (HBV) vaccine, and recent advances 
in antiviral therapy, chronic HBV infection has still re-
mained a public health concern among infected dialysis 
patients because it results in an increased risk of morbid-
ity and mortality (1). However, Alavian et al. have shown 
that the prevalence of HBV infection among hemodialy-
sis (HD) patients in Iran declined to 2.4 - 2.6% in 2005 (2, 
3). Furthermore, the clinical course and natural history 
of HBV infection are diﬀerent in dialysis and nondialysis 
patients, and it may lead to a unique clinical problem in 
dialysis subjects. In addition, limited data are available 
on the optimal therapy of chronic HBV infection in dialy-
sis patients. Therefore, in this article we discuss whether 
antiviral therapy is possible in infected dialysis patients 
with HBV.
2. Goals of Therapy 
Clearance of HBsAg with anti-HBs seroconversion is an 
important aim of treatment for all HBV antiviral thera-
pies. However, this goal can only be reached in a small 
proportion of immunocompetent patients, and reach-
ing this goal is likely to be even less frequent in immu-
nocompromised patients such as HD individuals (4). 
Parameters used to assess treatment response include 
normalization of serum alanine aminotransferase (ALT; 
biochemical response), decrease in serum HBV DNA 
level below the lower limit of detection of sensitive poly-
merase chain reaction (PCR) assays, loss of HBeAg with 
appearance of anti-HBe (HBeAg seroconversion) in pa-
tients who are HBeAg positive at baseline, and improve-
ment of liver histology (decline in necroinﬂammatory 
activity and no enhance in ﬁbrosis; (5). Moreover, the 
ultimate goal for treatment of chronic HBV is to prevent 
the development of irreversible complications such as 
cirrhosis, liver failure, and hepatic cancer. All dialysis 
patients using antiviral therapy against HBV infection 
should be monitored for response to therapy and for side 
eﬀects of drugs. The serum ALT levels of dialysis patients 
should also be regularly monitored; unfortunately, the 
biochemical response to therapy is diﬃcult to identify 
due to its depressed level in these patients (6). Although 
a decrease in serum HBV DNA viral load during treat-
ment appears to be the most important measure of re-
sponse to therapy and improved long-term patient out-
comes (7), HBV DNA levels are likely to be lower range in 
dialysis patients with HBV infection than in infected pa-
tients with normal renal function (8). According to AAS-
LD guidelines, all patients who are receiving therapy for 
HBV should have a liver panel measured every 3 months 
and HBV DNA levels quantiﬁed every 3 to 6 months (9). 154 Hepat Mon. 2012
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In addition, patients should also be monitored every 3 to 
4 months by serum alpha-fetoprotein levels and at least 
annually by liver ultrasound. Monitoring of HD patients 
with HBV infection during treatment is crucial for as-
sessing drug safety, patient compliance, and treatment 
responses. Early monitoring of HBV DNA is of particular 
value to detect primary treatment failure and predict 
outcomes of sustained therapy (e.g., improved liver 
histology, prevention or reduced likelihood of disease 
progression, and occurrence of drug resistance). Sugges-
tions for HBV DNA monitoring in patients on antiviral 
therapy are summarized in Table 1 (10).
3. Indications for Antiviral Therapy 
Deciding which dialysis patients with HVB infection 
should be treated is a controversial issue. In the case of 
patients with normal renal function, antiviral therapy 
for chronic HBV infection is indicated in those with ac-
tive virus replication (HBeAg positive and/or detectable 
serum HBV DNA) and active liver disease (raised ALT lev-
els; (11, 12). However, a scarcity of data exists concerning 
the optimal therapy of chronic HBV infection in dialysis 
patients. It is obvious that these patients present a dif-
ferent clinical and biochemical picture in chronic HBV 
infection (13). Dialysis individuals with HBV infection are 
less likely to have a symptomatic acute illness and are 
more likely to develop chronic carrier status (14). In inac-
tive carriers (i.e., dialysis patients with HBsAg and unde-
tectable HBV DNA), there is no indication to start antivi-
ral therapy, although monitoring for complications such 
as hepatocellular carcinoma should be undertaken (4). 
On the other hand, serum ALT levels tend to remain with-
in the normal range (15), and HBV DNA levels are likely to 
be lower in dialysis patients with HBV infection than in 
infected patients with normal renal function (8). There-
fore, in patients who are HBsAg-positive and have viral 
replication, a liver biopsy should be conducted, even in 
the presence of ALT within the normal range levels (4). 
Finally, those with high HBV DNA values or evidence of 
active inﬂammation on biopsy are candidates for initia-
tion of antiviral therapy (16).
4. Antiviral Agents
Seven drugs have received approval for the treatment of 
chronic HBV infection, including interferon-α, pegylated 
interferon-α, the nucleoside analogues lamivudine and 
telbivudine, and the nucleotide analogues adefovir, teno-
fovir, and entecavir. Entecavir, telbivudine, and tenofovir 
are the most potent, followed by lamivudine and then 
adefovir. Entecavir and tenofovir are associated with the 
lowest risk of drug resistance, followed by adefovir, telbi-
vudine, and lamivudine, in that order (17).
5. Interferon-Alfa
Interferon-α, an antiproliferative and immunomodu-
latory agent, was the ﬁrst available antiviral drug for 
chronic HBV infection. This agent is metabolized by re-
nal tubules. In dialysis patients, it has been found that in-
terferon- α’s half-life is greatly enhanced, and prolonged 
treatment can lead to drug accumulation; hence, its 
adverse eﬀects are magniﬁed and include ﬂu-like symp-
toms, nausea, diarrhea, fatigue, leucopenia, thrombocy-
topenia, thyroid dysfunction, alopecia, and depression 
(16). Therefore, interferon-α is poorly tolerated by dialysis 
patients who have a frequent occurrence of side-eﬀects, 
such as exacerbation of anemia, neutropenia, and pro-
tein malnutrition. Scarce data exist on treatment with 
interferon-α among infected dialysis patients with HBV. 
In one study, the adverse eﬀects were so severe that with-
drawal of the drug was required in more than 50% of 
patients (6). Newer, pegylated interferon, an agent with 
a longer half-life, is no better tolerated in patients with 
renal failure. Finally, interferons are not recommended 
in dialysis patients with HBV infection (16).
6. Lamivudine
Lamivudine is the ﬁrst nucleoside analogue antiviral 
approved worldwide for the treatment of chronic hepa-
titis B. Its major advantages include ease of administra-
tion (oral), potent antiviral activity, and favorable safety 
proﬁle. Lamivudine has also been shown to be eﬀective 
in the treatment of HBV-associated, acute glomerulone-
phritis (18). Because lamivudine is primarily excreted via 
the kidneys and renal impairment could lead to a three- 
or fourfold increase in its half-life, this drug targets the 
replication of the HBV genome and is well tolerated and 
safe with end-stage renal disease (ESRD) patients when 
the dose of drug is precisely adjusted for the degree of 
renal insuﬃciency. Good results were obtained in a se-
ries of 16 dialysis patients: 56% were able to eliminate 
HBV DNA and 36% were able to clear HbeAg (19). The main 
disadvantages of lamivudine include risk for drug resis-
tance and the need for a long duration of treatment. De-
spite its promising short-term eﬃcacy, the widespread 
Treatment duration, y HBV DNA Interpretation
1 ≥ 10 IU/mL or ≥ 50 copies/mL reduction from baseline Virologic response
1 < 10 IU/mL or < 50 copies/mL reduction from baseline Primary treatment failure
2 Undetectable by PCR Complete virologic response
2 ≥ 60 to < 2000 IU/mL (or ≥ 300 to < 10,000 copies/mL) Partial virologic response
2 > 2000 IU/mL (or > 10,000 copies/mL) Inadequate virologic response
Table 1. HBV DNA Monitoring During Antiviral Therapy155 Hepat Mon. 2012
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and long-term use of lamivudine monotherapy has led 
to a progressive increase in the numbers of patients with 
HBV resistance to lamivudine after prolonged treatment; 
for example, Fontaine et al. showed that lamivudine-
resistant HBV develops in 39% of dialysis patients after 
a median of 16.5 months of treatment (20). The preva-
lence of drug resistance enhanced with the duration of 
the therapy, and it was detectable in 14% of patients who 
were continuously treated for one year and in 69% of pa-
tients who were treated for 5 years (6). Despite the risk 
of mutational resistance, lamivudine requires continued 
use for prolonged treatment (16). On the other hand, the 
development of drug-resistant variants after prolonged 
therapy with lamivudine is a major limitation (12, 20). 
Nonetheless, there are still some problems with using 
lamivudine in dialysis patients. It is important to note 
that patients’ treatment response could be assessed by 
serum ALT levels; however, serum transaminase levels 
tend to remain within the normal range or just slightly 
higher. In addition, the overall eﬀects and outcomes of 
lamivudine therapy in dialysis patients remain unclear, 
and further studies are required for clariﬁcation (6). The 
high occurrence of drug resistance may result in poten-
tially life-threatening exacerbation of liver disease. 
7. Adefovir Dipivoxil
Adefovir dipivoxil, a nucleotide analogue, is the second 
oral agent approved for the treatment of chronic HBV 
infection. It is usually added to therapy for lamivudine-
resistant patients (21). Adefovir is eﬀective in patients 
with HBV infection who have normal renal function, 
although a very high relapse rate is seen if this drug is 
stopped; for example, relapse was observed in 92% of in-
dividuals with normal renal function in whom adefovir 
was discontinued after 48 weeks of the treatment (22). 
Resistance is much less common than with lamivudine; 
0% at one year and 29% at 5 years (23). This makes adefovir 
an option for add-on therapy in patients who have devel-
oped lamivudine resistance (24). Furthermore, adefovir 
is a nephrotoxic agent (6), and worsened renal function 
has been reported in 2.5 to 28.0% of cases after 1 to 2 years 
of therapy (6). Limited data about adefovir administra-
tion exist in the chronic kidney disease (CKD) population 
(25, 26). Adefovir is eliminated via the kidneys; thus, a 
dose adjustment is required in CKD patients to prevent 
drug accumulation and its side eﬀects (21). In one study, 
adefovir was used in a series of 12 patients with CKD who 
had lamivudine-resistant HBV; a signiﬁcant reduction 
was observed in HBV DNA viral loads after a median of 
15 months of treatment (25). Additionally, a case study 
described successful treatment of HBV infection in a 
dialysis-dependent liver-transplant recipient who had 
lamivudine-resistant infection and cirrhosis of the al-
lograft (26). 
8. Entecavir
Entecavir is a promising nucleoside analogue drug that 
has selective anti-HBV activity, especially against lamivu-
dine-resistant HBV. Although no long-term data exist for 
lamivudine, the rate of entecavir resistance appears to be 
minimal, only about 1% after 3 years of monotherapy (27). 
Entecavir is eﬀective in viral suppression; however, the 
emergence of entecavir resistance with prolonged treat-
ment could pose a dilemma (28, 29). In one study, ente-
cavir treatment in subjects with normal renal function 
was associated with a signiﬁcant decrease in HBV DNA 
viral load compared to lamivudine and adefovir (16). 
Although the ﬁeld has established little information on 
the therapeutic impact of entecavir in dialysis patients 
with chronic HBV infection, it is often recommended as a 
ﬁrst-line oral therapy in patients with kidney disease (16). 
Therefore, the optimal duration of treatment for these 
patients as well as the relationship between treatment 
and long-term outcomes such as cirrhosis and hepato-
cellular carcinoma remain unknown. Because entecavir 
is primarily eliminated by the kidneys, dose reduction 
is recommended for dialysis patients (30). Moreover, the 
drug should be administered after hemodialysis, and 
continuous ambulatory peritoneal dialysis can remove 
approximately 0.3% of the dose over 7 days. It should be 
noted that entecavir has to be administered on an empty 
stomach (at least 2 hours after a meal or at least 2 hours 
before the next meal). 
9. Tenofovir
The nucleotide analog tenofovir is recommended as a 
ﬁrst-line oral antiviral in the treatment of chronic HBV 
patients with normal renal function (31). It is the most 
potent agent against HBV infection within the ﬁrst year 
of treatment (32). Tenofovir can also be an eﬀective al-
ternative in patients with lamivudine-resistant HBV 
infection and has greater HBV DNA suppression, more 
normalized ALT levels, and a greater loss of HBsAg than 
adefovir (33). However, nephrotoxicity and acute kidney 
injury have been reported in some patients treated with 
tenofovir (34-38); therefore, the drug should be avoided 
in dialysis patients with residual renal function. A case 
report showed that one weekly dose of 300 mg of tenofo-
vir was eﬀective in a single HBV-infected dialysis patient 
(39). This ﬁnding was replicated by the manufacturers of 
the drug in a study of 9 dialysis patients (40).
10. Telbivudine
Telbivudine is a synthetic thymidine nucleoside ana-
logue that inhibits HBV DNA polymerase (41). Telbivu-
dine is a potent anti-HBV drug that provides eﬀective and 
sustained viral suppression (42). In clinical trials, telbivu-
dine has been superior to lamivudine in HBV patients in 
terms of treatment outcomes and HBV DNA suppression 
after 1, 2, and 4 years of therapy (42, 43). When compared 
with lamivudine, telbivudine has greater HBV-DNA sup-
pression (down to undetectable levels) at weeks 24 and 
104, and HBeAg seroconversion rates are signiﬁcantly 
greater with telbivudine than with lamivudine (44). In 156 Hepat Mon. 2012
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addition, telbivudine-treated subjects have signiﬁcantly 
less viral resistance than do lamivudine-treated individ-
uals (9, 42). After 2 years of therapy, resistance to telbivu-
dine emerged rarely in those who had a complete viral 
response at 6 months (9). In a study on Chinese patients 
with chronic hepatitis B, telbivudine treatment for 52 
weeks provided greater antiviral and clinical eﬃcacy 
than lamivudine, with less resistance (45). Telbivudine 
was also well tolerated in clinical trials for periods of up 
to 4 years with minor side eﬀects (42). Thus, telbivudine 
can be considered a valuable agent in the treatment of 
chronic HBV infection (42). In a study that evaluated the 
eﬀect of renal insuﬃciency on the pharmacokinetics of 
telbivudine, 36 cases received a single oral dose of tel-
bivudine, adjusted on the basis of creatinine clearance. 
Telbivudine was well tolerated by all subjects. This study 
showed that the pharmacokinetics of telbivudine were 
dependent on renal function, especially for subjects with 
moderate to severe renal dysfunction or ESRD. These re-
sults indicated that although no adjustment of the tel-
bivudine dose appears necessary for subjects with mild 
renal insuﬃciency, dose adjustment is warranted for 
those with moderate to severe renal impairment or ESRD 
in order to achieve optimal plasma exposure (46). Telbi-
vudine may be used for the treatment of chronic hepati-
tis B in patients who have impaired renal function. The 
drug is eliminated primarily through the kidneys; there-
fore, dose adjustment is recommended in patients with 
creatinine clearance of less than 50 mL/min, including 
dialysis patients. A hemodialysis session, routinely 3.5 
to 4 hours, can reduce telbivudine from a patient’s plas-
ma by approximately 23% (46), and no additional dose 
modiﬁcation is necessary during routine hemodialysis. 
Furthermore, telbivudine should be administered after 
hemodialysis sessions when given on hemodialysis days.
11. Conclusions
In summary, treatment of HBV infection is changing 
with time. Lamivudine is no longer regarded as the ﬁrst-
line treatment for chronic hepatitis B due to high rates of 
drug resistance. One cause of antiviral failure is the use 
of a less potent agent, such as adefovir (4), which seems 
to function better as an add-on therapy in patients who 
have developed lamivudine resistance. In addition, ad-
efovir has not been well examined in dialysis patients. 
Although, tenofovir and entecavir are likely to be more 
eﬀective and safer in dialysis patients, long-term empiri-
cal data are very limited on these drugs. It seems that en-
tecavir can be administrated as a ﬁrst-line oral therapy in 
dialysis patients, but progressive emergence of entecavir 
resistance with prolonged treatment could pose a prob-
lem. No data about telbivudine administration exist in 
dialysis patients. Finally, the best approach to managing 
these patient populations is still vaccination against HBV 
along with isolation of infected patients during hemodi-
alysis sessions (1, 47).
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